Biotechnology company that develops novel drugs for Alzheimer's disease and cancer
IntelliHep is exploiting novel technologies and intellectual property to deliver new heparin-based glycans as novel drug leads for specific diseases including Alzheimer’s disease and cancer. This is being achieved through in-house R&D and the development of strategic collaborative alliances with external partners.
IntelliHep has developed from work initiated by the Founders at the Universities of Birmingham and Liverpool, and is currently based in the MerseyBio incubator at Liverpool University.
Visit website: http://www.intellihep.com/